Eli Lilly’s most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $262.50 short call and a strike $267.50 long call offers a potential 33.69% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $262.50 by expiration. The full premium credit of $1.26 would be kept by the premium seller. The risk of $3.74 would be incurred if the stock rose above the $267.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 43.91 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
AbbVie Stock Dropped After FDA Warning. Analysts Say Selloff Is Overblown.
Thu, 02 Sep 2021 19:04:00 +0000
The regulator said a class of drug known as JAK inhibitors increased the risk of cancer, serious heart-related events, and death.
Why Is Lilly (LLY) Down 1.9% Since Last Earnings Report?
Thu, 02 Sep 2021 15:31:03 +0000
Lilly (LLY) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.
FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels
Thu, 02 Sep 2021 13:17:01 +0000
The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer’s (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte’s (INCY) Olumiant, and AbbVie’s (ABBV) Rinvoq.
FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know
Thu, 02 Sep 2021 12:34:09 +0000
The FDA wrapped up its long-awaited review of Pfizer Inc’s (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR compared to tumor necrosis factor (TNF) blockers. What Happened: The agency said the trial results showed an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with the lower dose of Xeljanz. But, previous interim results showed the risk only with the higher dose. The FDA is updatin
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Wed, 01 Sep 2021 21:50:09 +0000
Eli Lilly (LLY) closed the most recent trading day at $257.40, moving -0.34% from the previous trading session.
Follow Us on Facebook